What Is Fabry Disease?
Fabry Disease (FD) is a rare X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene, which triggers a wide spectrum of clinical manifestations. The global incidence of Fabry Disease is approximately 1 in 100,000 individuals.
FD is categorized into two clinical subtypes: classic and late-onset non-classic forms.
- The classic subtype generally manifests in childhood or adolescence, with earlier and more severe symptoms predominantly observed in male patients. Key presentations include neuropathic pain, acroparesthesia, and episodic acute pain attacks termed “Fabry crises”. Progressive complications involving the heart, kidneys and cerebrovascular system develop in advanced disease stages.
- The non-classic subtype presents symptoms later in life (40–60 years of age), featuring prominent cardiac pathologies such as cardiac hypertrophy, left ventricular hypertrophy, cardiomyopathy, hypertrophic cardiomyopathy and myocardial infarction, as well as end-stage renal disease.
Figure source: PubMed
Main clinical manifestations of Fabry Disease
Pathogenesis
Fabry Disease arises from mutations in the GLA gene located at chromosomal locus Xq22.1. These variants induce reduced or complete loss of α-galactosidase A (α-Gal A) enzymatic activity, leading to massive intracellular accumulation of the glycosphingolipid substrate globotriaosylceramide (GL-3) and its deacylated derivative lyso-GL-3 across multiple tissues and organs, ultimately causing multi-organ damage and premature mortality.
Specific GLA variants including c.337T>C (p.F113L), p.N215S, p.M296I, p.R301Q, p.G328R and IVS4+919G>A are associated with the late-onset cardiac phenotype of Fabry Disease.
Schematic diagram of ATP7B copper transporter structure (Source: PubMed)
Therapeutic Strategies Based on Gene Therapy
1. Adeno-Associated Virus (AAV) Vectors
AAV vectors deliver functional wild-type GLA transgenes to patients. This platform enables safe and efficient hepatic gene delivery with minimal immune response and systemic toxicity.
2. Hematopoietic Stem and Progenitor Cells (HSPCs)
Lentiviral vectors mediate stable GLA gene integration into HSPCs, which are subsequently infused back into patients. This approach durably halts disease progression and may eliminate the need for repeated therapeutic intervention.
3. mRNA Therapy
Exogenous mRNA encoding functional α-Gal A is delivered to target cells, driving endogenous translation of enzymatically active protein to restore metabolic function.
4. Gene Editing
Gene editing tools enable precise removal of pathogenic genomic fragments, targeted insertion of corrected gene sequences, and single-base pair conversion to rectify disease-causing mutations.
Research Mouse Models for Fabry Disease
1. Gla Knockout Mice
Targeted ablation of the murine Gla gene recapitulates the core pathological hallmark of Fabry Disease: absent α-Gal A activity and progressive GL-3 glycosphingolipid deposition across multiple organs.
2. G3S / Gla Double Knockout Mice
On a Gla-null background, these strains overexpress human Gb3 synthase (G3S). This genetic modification drastically accelerates GL-3/Gb3 lipid accumulation in tissues, generating a pathological phenotype that more closely recapitulates severe human Fabry Disease compared to single Gla knockout lines.
3. IVS4+919G>A Mutant Knock-In Mice
This model harbors the human IVS4+919G>A splice-site variant of Gla, which is genetically linked to late-onset cardiac manifestations of Fabry Disease, supporting cardiovascular mechanism and drug development research.
MingCeler Biotech Supports Gene Therapy Development
Gene therapy delivers promising therapeutic prospects for rare diseases, yet preclinical development and efficacy validation are highly dependent on standardized animal models.
Powered by our proprietary TurboMice™ technology, MingCeler Biotech has generated a broad panel of rare disease mouse models. TurboMice™ overcomes two major limitations of traditional model construction: lengthy breeding cycles and low success rates for complex genetically modified strains. The platform supports precise editing of nearly any target genomic locus and generates fully homozygous gene-edited mouse lines directly from embryonic stem cells in as little as 2 months.
MingCeler Biotech provides custom Fabry Disease mouse models tailored to client research demands, including Gla knockout mice, G3S/Gla double knockout mice, and IVS4+919G>A knock-in mutant mice. All academic and industrial researchers are welcome to contact our technical team for project consultations!
References
[1] Ouyang Y, Ren H, Chen N. Advances in precision therapy for Fabry disease. Chin J Nephrol. 2023, 39(4): 298-304. DOI: 10.3760/cma.j.cn441217-20220831-00850.
[2] Borisch C, Thum T, Bär C, et al. Human in vitro models for Fabry disease: new paths for unravelling disease mechanisms and therapies. J Transl Med. 2024;22:965. https://doi.org/10.1186/s12967-024-05756-w.
[3] Ruangsiriluk W, Deshpande M, Boukharov N, et al. Reversing Pathology in an Aggravated Fabry Mouse Model Using Low-Dose Engineered Human Alpha-Galactosidase A AAV Gene Therapy. Biomedicines. 2025;13(3):577. https://doi.org/10.3390/biomedicines13030577.
[4] Sorriento D, Iaccarino G. The Cardiovascular Phenotype in Fabry Disease: New Findings in the Research Field. Int J Mol Sci. 2021;22(3):1331. doi:10.3390/ijms22031331. PMID: 33572752; PMCID: PMC7865937.
[5] Pieroni M, Ciabatti M, Graziani F, et al. The Heart in Fabry Disease: Mechanisms Beyond Storage and Forthcoming Therapies. Rev Cardiovasc Med. 2022;23(6):196. doi: 10.31083/j.rcm2306196. PMID: 39077177; PMCID: PMC11273771.
Previous Article: Rare Diseases Focus | Issue 12: Hepatolenticular Degeneration (Wilson Disease)
Next Article: Rare Diseases Focus | Issue 14: Neuromyelitis Optica Spectrum Disorder